Novel mutations of the MET proto-oncogene in papillary renal carcinomas-Reference-Cited by-同舟云学术

Novel mutations of the MET proto-oncogene in papillary renal carcinomas

Published:1999-04 Issue:14 Volume:18 Page:2343-2350
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Schmidt Laura,Junker Kerstin,Nakaigawa Noboru,Kinjerski Tracy,Weirich Gregor,Miller Maria,Lubensky Irina,Neumann Hartmut PH,Brauch Hiltrud,Decker Johann,Vocke Cathy,Brown James A,Jenkins Robert,Richard Stephane,Bergerheim Ulf,Gerrard Bernard,Dean Michael,Linehan W Marston,Zbar Berton

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/1202547.pdf

Reference37 articles.

1. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grubendorf F, Raue F, Ritter MM and Hoppner W. . 1998 J. Clin. Endo. Metab. 83: 770–774.

2. Borden EC, Hogan TF and Voelkel JG. . 1982 Cancer Res. 42: 4948–4953.

3. Brown JA, Anderl KL, Borell TJ, Qian J, Bostwick DJ and Jenkins RB. . 1997 J. Urology 158: 370–374.

4. Di Renzo MF, Olivero M, Serini G, Orlandi F, Pilotti S, Belfiore A, Costantino A, Vigneri R, Angeli A, Pierotti MA and Comoglio PM. . 1995 J. Endocrinol. Invest. 18: 134–139.

5. Duh F-M, Scherer SW, Tsui L-C, Lerman M, Zbar B and Schmidt L. . 1997 Oncogene 15: 1583–1586.

Cited by 448 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma;BJU International;2024-07-16

2. Recording and classifying MET receptor mutations in cancers;eLife;2024-04-23

3. Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma;Journal of Pharmaceutical and Biomedical Analysis;2024-03

4. Papillary Renal Cell Carcinoma: Evolving Classification by Combined Morphologic and Molecular Means;Advances in Anatomic Pathology;2024-02-08

5. Receptor tyrosine kinases: biological functions and anticancer targeted therapy;MedComm;2023-12